Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Live Nation Entertainment, Inc. (LYV) Price & Performance

Bristol-Myers Squibb CoTrade
Live Nation Entertainment, Inc.Trade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Live Nation Entertainment, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.65 (market cap $129.94B), while Live Nation Entertainment, Inc. trades at $185.01 (market cap $42.71B). The key difference: Bristol-Myers Squibb Co is far larger — about 3× Live Nation Entertainment, Inc.'s market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals.

BMYLYV
Market Cap
$129.94B$42.71B
Sector
HealthIndustrials
52-Week High
$65.89$186.59
52-Week Low
$42.60$125.61
Enterprise Value
$163.92B$44.92B
Dividend Yield
3.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.

BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.

Live Nation Entertainment, Inc.

Live Nation (LYV) trades at $184.65, showing minimal daily movement (+0.01%) amid strong analyst support with 87% buy ratings. The stock maintains a bullish technical outlook with key resistance at $186 and support at $181. Recent Q2 2026 earnings beat expectations with $1.05 EPS versus $0.66 estimate, driven by record concert attendance and international demand growth. Revenue reached $25.2B in 2025, though net margins remain thin at 0.51%.

The outlook remains positive given robust demand for live events and raised 2026 guidance, but high valuation multiples (P/E 117.5) and legal/regulatory risks warrant caution. Insider selling activity and negative ROE (-116.7%) highlight execution challenges despite strong top-line performance. Upside to consensus $209.54 target depends on margin expansion and debt management.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Live Nation Entertainment, Inc.

Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.

Read more on LYV